TriSalus Life Sciences Inc（TLSI）财务数据TLSITriSalus Life Sciences Inc

Evaluating the bottom line, TriSalus Life Sciences Inc maintains a gross margin of 86.78%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -86.03%, while the net margin is -80.54%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively TLSI converts its operational activities into shareholder value.

In the context of the broader market, TLSI competes directly with industry leaders such as CV and MYGN. With a market capitalization of $303.56M, it holds a leading position in the sector. When comparing efficiency, TLSI's gross margin of 86.78% stands against CV's 51.36% and MYGN's 66.60%. Such benchmarking helps identify whether TriSalus Life Sciences Inc is trading at a premium or discount relative to its financial performance.

The company reported a gross margin of 86% in Q2 2026, indicating strong profitability potential, but has faced significant net income losses, with a net loss of $9.19 million in the same quarter.